← 글 목록← All articles

Supreme Court en banc Decision 2014Hu768 Decided May 21, 2015: are administration and dosage (a dosage regimen) an element of the invention in Korea?

Brief summary

  • The Supreme Court of Korea held that administration and dosage (dosage regimen and dose) added to an invention of a medicine as a product can be an element of the invention. This applies where they are added together with the target disease or efficacy. [1]
  • A new patent right can be granted to a medicine that meets the requirements for patentability, such as novelty and inventive step, by the addition of administration and dosage. The Supreme Court overruled the 2009 decisions that had held otherwise. [1]
  • An invention of a process that claims the method of treating humans as such is still not allowed after this decision. The final appeal in this case was dismissed. The reason is that the accused invention (challenged invention) was a free-to-work technology (technology that could be easily implemented from the publicly known art). [1]

Last verified

The case

Item Details
Court Supreme Court of Korea
Date of decision 21 May 2015
Case number 2014Hu768
Case name Confirmation of the Scope of Rights (Patent) (the Supreme Court’s English text of this decision: Confirmation of the Scope of Patent Right)
Lower court Patent Court Decision 2013Heo5759 Decided April 11, 2014
Result The final appeal is dismissed. Part of the party indications in the lower judgment was corrected
En banc or not En banc decision. There is a Concurring Opinion by 2 Justices and an Opinion concurring with the Majority Opinion by 1 Justice
Decisions overruled Supreme Court Decision 2007Hu2926 Decided May 28, 2009, Supreme Court Decision 2007Hu2933 decided on the same day, and decisions to the same effect
Reference Provisions (as stated in the decision) Former Patent Act (구 특허법) (before amendment by Act No. 3891 of 31 December 1986), Art. 4, subparagraph 3 (currently deleted) and subparagraph 5 (currently deleted); Patent Act (특허법), Art. 2, subparagraph 3 and Art. 96(2); Medical Service Act (의료법), Art. 12(1)

The content of this table is taken from the written judgment. [1]

The issue: are the administration and dosage stated in a claim an element of the invention?

The issue is whether the administration and dosage stated in the claims of a medical use invention (medicinal use invention) can be regarded as an element of the invention. [1]

The earlier decisions did not regard them as an element. This decision summarizes the earlier decisions in two points. The first is that the administration interval and the unit dosage are a method of administering a pharmaceutical substance to humans and the like, and so are medical practice. The second is that they do not relate to the final product itself that results from the statements in the claims. [1]

This case began as a trial to confirm the scope of a right (권리범위 확인심판). A trial to confirm the scope of a right is a trial to have the scope of protection of a patented invention confirmed (Patent Act, Art. 135). [6] The accused invention, which was the subject of the trial, was a medicine for treating a certain disease. It was already publicly known that the compound that is its active ingredient is effective as a medicine for treating that disease. The lower court found that the technical feature of one element of the accused invention lies in limiting the dosage to 1 mg and the administration interval to once a day. [1]

The lower court, the Intellectual Property High Court of Korea (Patent Court of Korea) (특허법원), decided on the premise that the administration interval and the dosage are elements of the invention. The lower court found that the accused invention is a free-to-work technology. It therefore held that the accused invention does not fall within the scope of the right of the patented invention, without any need to compare the two. The plaintiff side filed a final appeal. [1]

What the court held 1: a medical use is an element of an invention of a product, not of a process

The Majority Opinion first set out what a medical use invention is. A medical use invention is based on the discovery of an unknown property, namely a specific pharmacological effect that a pharmaceutical substance has. It is an invention that, on the basis of that discovery, provides a new use in which the substance shows efficacy as a medicine. [1]

The Majority Opinion stated that the Korean Patent Act no longer has any ground for denying the patentability of a medical use invention. Art. 4 of the Patent Act before its amendment on 31 December 1986 listed the inventions for which a patent could not be obtained. Subparagraph 3 was an invention of a substance that can be manufactured by a chemical process, and subparagraph 5 was an invention concerning the use of a chemical substance. Act No. 3891 deleted these two subparagraphs. [1] [6]

Act No. 3891 also deleted Art. 4, subparagraph 2 at the same time. Subparagraph 2 was an invention of a medicine and an invention of a process for manufacturing one medicine by mixing two or more medicines. Act No. 3891 was promulgated on 31 December 1986 and entered into force on 1 July 1987. The Addenda provided that the examination of a patent application filed before the entry into force is governed by the former provisions. [6]

The Majority Opinion distinguished an invention of a process from an invention of a product. An invention concerning medical practice, such as the diagnosis, relief, treatment, therapy and prevention of human diseases, is excluded from the subject of a patent. A medical use invention therefore cannot be allowed as an invention of a process whose subject is the method of treating humans and the like as such. By contrast, an invention that adds a medical use to a medicine, which is a product, can newly be the subject of a patent as an invention of a product. [1] Here the Majority Opinion cited a 1991 decision. That decision held that an invention concerning medical practice that uses a medicine on humans is not an invention that can be used in industry. The 1991 decision also stated an exception. It held that an invention whose claims expressly state that it is claimed only for animals is the subject of a patent. [3]

The Majority Opinion stated that, in a medical use invention written in the form of an invention of a product, the pharmaceutical substance and its medical use constitute the invention. This medical use is not medical practice itself. It is an element of the invention that expresses the property by which a medicine, which is a product, shows its efficacy. [1] Supreme Court Decisions 2006Hu3564 and 2012Hu3664, which the Majority Opinion cited, also held that the use of a medicine constitutes the invention. [4] [5]

What the court held 2: administration and dosage share the nature of a medical use

The Majority Opinion stated that administration and dosage are “the same in nature” as a medical use concerning the target disease or efficacy. [1] The Majority Opinion gave three reasons.

  • For a medicine to show its efficacy fully, not only the target disease but also the administration and dosage must be set appropriately. As examples of administration, the Majority Opinion gave the administration interval, the site of administration and the route of administration. [1]
  • Administration and dosage also provide a new use on the basis of the discovery of an unknown property, namely the pharmacological effect of a pharmaceutical substance. [1]
  • Even for the same medicine, a change in the administration and dosage can produce an unexpected effect. As examples, the Majority Opinion gave enhanced efficacy, reduced side effects and greater convenience of administration. Developing them also costs no less than developing a target disease or efficacy. [1]

The Majority Opinion then referred to the purpose of the Patent Act. It stated that “fundamentally denying” protection as a patent, before any examination of novelty, inventive step and the like, is not consistent with the purpose of the Patent Act. [1]

The conclusion is two sentences. First, administration and dosage that are added, together with the target disease or efficacy, to an invention of a medicine as a product can be an element of the invention. They are not medical practice itself but an element that gives a new meaning to the medicine as a product. Second, such administration and dosage are a new medical use. A new patent right can be granted to a medicine that meets the requirements for patentability, such as novelty and inventive step, by their addition. [1]

The Majority Opinion stated that this legal principle applies in the same way to a trial to confirm the scope of a right. This is when determining whether the accused invention could be easily implemented from the publicly known art. [1]

What the court held 3: the accused invention in this case is a free-to-work technology

The Supreme Court accepted the lower court’s determination as it stood. The lower court regarded the dosage and the administration interval of the accused invention as elements and compared them with the publicly known art. The lower court found that a person skilled in the art could easily derive that element from the cited inventions. It also found that the effect was at a level that could be predicted from the cited inventions. [1]

The circumstances that the lower court relied on are as follows. Material on a single daily dose of 5 mg was publicly known, so it could be predicted that an effect would appear at 5 mg or less. The mean elimination half-life in the phase 1 clinical trial was 55 hours, so it could be predicted that administration once a day was possible. Another cited invention stated an amount administered of 0.5 to 2.5 mg, given orally every day, at the phase 2 clinical trial stage. The lower court found that the other element of the accused invention, the way the tablet is manufactured, is also easily derived from the cited inventions and well-known and commonly used art. [1]

The Supreme Court held that the lower court’s determination was justified and dismissed the final appeal. [1] In a case in which administration and dosage were recognized as elements, those elements were held to be easily derived from the publicly known art.

The Concurring Opinion and the Opinion concurring with the Majority Opinion

2 Justices gave a Concurring Opinion. The Concurring Opinion agreed with the conclusion that the final appeal cannot be accepted. However, it stated that administration and dosage cannot be regarded as an element of the invention even if they are stated in the claims. [1] The Concurring Opinion gave the following reasons.

  • Once the pharmaceutical substance and the target disease or efficacy are specified, adding administration and dosage does not make a separate new medical use invention. [1]
  • Setting the administration and dosage is a change in the way of use, and it is realized through medical practice. A medical doctor must be able to decide the administration and dosage freely on the basis of professional knowledge. [1]
  • An invention of a product does not have the “passage of time” as one of its elements. Administration and dosage include this element. [1]
  • How far the subject of a patent should be recognized also needs to be decided as a matter of policy, taking into account Korea’s economic situation and the level of development of its industry. [1]

1 Justice gave an Opinion concurring with the Majority Opinion. This opinion stated that recognizing patentability does not mean that a patent is granted as a matter of course. Efforts to find appropriate administration and dosage are ordinarily made in the process of pharmaceutical development. It therefore stated that a patent should be granted only to administration and dosage that show “a remarkable effect or an effect of a different kind” that a person skilled in the art could not predict. This opinion stated that this determination can be made in the examination of novelty, inventive step and the like. [1]

What the court did not decide

The Majority Opinion did not set the standard by which the inventive step of an invention concerning administration and dosage is determined. The Majority Opinion said only a medicine “that meets the requirements for patentability, such as novelty and inventive step”. The expression “a remarkable effect or an effect of a different kind” appears in the Opinion concurring with the Majority Opinion. [1]

The Supreme Court did not decide the novelty or inventive step of the patented invention in this case itself. The lower court reached its conclusion without any need to compare the accused invention with the patented invention, and the Supreme Court upheld that determination. [1]

The Supreme Court also did not decide whose acts, and which acts, are covered by the patent right for a medicine limited by administration and dosage. This case is not patent infringement litigation but a case of a trial to confirm the scope of a right. [1]

Before and after this decision: it overruled the 2009 decisions, and a 2017 decision stated the standard for inventive step

This decision overruled earlier precedents. What was overruled is Supreme Court Decision 2007Hu2926 Decided May 28, 2009, Supreme Court Decision 2007Hu2933 decided on the same day, and decisions to the same effect. They were overruled to the extent that they are inconsistent with the view of this decision. [1]

The two overruled decisions are not carried in the case law of the Korean Law Information Center (국가법령정보센터) of the Ministry of Government Legislation (법제처) (checked on 9 October 2026). This article states the effect of the two decisions only as the written judgment in 2014Hu768 summarizes it. [1]

A 2017 decision stated the standard for the inventive step of a use invention concerning administration and dosage. It is Supreme Court Decision 2014Hu2702 Decided August 29, 2017. This decision held that, for inventive step not to be denied, “a remarkable effect or an effect of a different kind” that a person skilled in the art could not predict must be recognized. The basis for the determination is the state of the art at the time of filing, the publicly known art and the like. The reason is that efforts to find appropriate administration and dosage are ordinarily made in the process of pharmaceutical development. [2]

The 2017 decision concerned a medical use invention that provides transdermal administration as the administration. The Supreme Court found that this transdermal use is an effect of a different kind that a person skilled in the art could not predict. The Supreme Court reversed the lower judgment, which had denied inventive step, and remanded the case to the IP High Court of Korea. [2] The written judgment of the 2017 decision does not cite Decision 2014Hu768. The expression “a remarkable effect or an effect of a different kind” appears both in the Opinion concurring with the Majority Opinion in Decision 2014Hu768 and in the 2017 decision. [1] [2]

Whether Decision 2014Hu768 was itself overruled later was also checked. A search of the case law of the Ministry of Government Legislation did not return an en banc decision that decided this issue again (searched on 9 October 2026).

How examination practice states it

The revision history of the Patent Examination Guidelines (특허·실용신안 심사기준) records a revision in November 2016. That line reads “revision of the examination guidelines on inventions limited by administration and dosage, etc.” [8]

Current examination practice is in Chapter V, Pharmaceutical Field, of the Examination Practice Guidelines by Technology Field (기술분야별 심사실무가이드) (March 2026 edition) of the Ministry of Intellectual Property (MOIP, 지식재산처). These Practice Guidelines are not a statute. They are guidance on the examination practice of examiners. The last revision recorded in the history of Chapter V is December 2021. [7]

Item What the Practice Guidelines state Place in the Practice Guidelines
Scope of administration and dosage The administration interval, the time of administration, the order of administration, the site of administration, the route of administration, the amount administered and the like 1.3 (2)
Claim format A medical use invention is in principle written in the form of a composition 2.2.1.1
Method of treatment An invention concerning a method of treating human diseases and the like is regarded as an invention that is not industrially applicable. The same applies if the method is in substance such a method, even where the claims are not written in that way 3.1.1
Specification The pharmacological effect that supports the medical use, including the administration and dosage, must be stated at the time of filing. An exception applies where there are special circumstances, such as where the pharmacological mechanism has been clearly established 2.1.1.1
Novelty A medical use invention of a publicly known substance cannot be regarded as identical as long as the use, including the administration and dosage, is different. Even where the medical use is expressed differently, the invention is regarded as lacking novelty if the pharmacological effect is judged to be based on an identical or closely related pharmacological action 3.3.1
Inventive step The limitation of administration and dosage is recognized as an element in the determination. If that element produces a remarkable effect that a person skilled in the art could not predict, and the invention is recognized as worth protecting by a patent, it is regarded as involving an inventive step 3.4.1.3

The content of this table is all taken from the Practice Guidelines. [7]

The Practice Guidelines state that the pharmacological effect must in principle be supported by clinical trials. They add that, depending on the content of the invention, it may be stated by animal tests or in vitro tests. [7] The Practice Guidelines give one more case that lacks novelty. It is the case where the subject to which the medicine is applied, the means of application, the time of application and the like cannot be distinguished in substance. [7]

The Practice Guidelines give Decision 2014Hu768 as an example under the inventive step item. It is an example of the case where a similar administration and dosage are stated in the cited invention. The Practice Guidelines state that optimizing the unit dosage and the method of administration is a technical matter of the level ordinarily carried out in the pharmaceutical field. [7]

This example in the Practice Guidelines is written in the form of comparing a claim with a cited invention. What the decision compared with the publicly known art is not the patented invention but the accused invention. The Supreme Court did not decide the inventive step of the patented invention itself. [1] [7]

The inventive step item of the Practice Guidelines says “a remarkable effect”. The 2017 decision said “a remarkable effect or an effect of a different kind”. [2] [7]

Have the provisions cited in the decision changed since then?

The wording that bears on the conclusion of the decision has not changed. Among the Reference Provisions of the decision, the Patent Act provisions are Art. 2, subparagraph 3 and Art. 96(2). [1]

  • Art. 96(2) is a provision on an invention of a medicine manufactured by mixing two or more medicines and an invention of a process for manufacturing it. The effect of that patent right does not extend to the preparation of prescriptions under the Pharmaceutical Affairs Act (약사법) or to medicines prepared according to such prescriptions. The parenthesis in this paragraph defines a medicine. A medicine is a product used for the diagnosis, relief, treatment, therapy or prevention of human diseases. The wording of Art. 96(2) is the same in the version at the time of the decision (Act No. 13317) and the current version (Act No. 21134). [6]
  • Art. 2, subparagraph 3 defines working (practice) separately for an invention of a product, an invention of a process, and an invention of a process for manufacturing a product. These three categories are the same at the time of the decision and now. [6]
  • The acts of working in Art. 2, subparagraph 3 were extended twice. Act No. 16804 added the act of offering the use of the method to item (b). This amendment entered into force on 11 March 2020. Act No. 20700 added exporting to items (a) and (c). This amendment entered into force on 22 July 2025. [6]
  • The Addenda of the two Acts have no applicability provision or transitional measure concerning Art. 2. The Addenda of Act No. 16804 set only the enforcement date. Art. 2 of the Addenda of Act No. 20700 is an applicability provision concerning patent term extension. [6]

Art. 135 is not among the Reference Provisions of the decision, but it is the provision on which the trial in this case was based. Art. 135(1) at the time of the decision stated the petitioner in one paragraph as a patentee, an exclusive licensee or an interested party. Act No. 14035 divided this into two paragraphs. The current paragraph (1) is the trial for which a patentee or an exclusive licensee files a petition concerning its own patented invention. The current paragraph (2) is the trial for which an interested party files a petition concerning another person’s patented invention. Act No. 14035 was promulgated on 29 February 2016 and entered into force on 1 March 2017. Its Addenda have no applicability provision or transitional measure concerning Art. 135. [6]

Act No. 21955 was promulgated on 15 September 2026 and enters into force on 16 March 2027. This Act does not change Art. 2, 29, 96 or 135 of the Patent Act. [6]

How claims to a method of treating humans are handled in Korea is covered in “Are method-of-treatment claims allowed in Korea?”.

What changes in practice

The following is the view of our firm. The assessment of an individual application or case depends on its facts, so please check with your agent.

  • At the filing stage, we suggest stating the administration and dosage inside the claim to the medicine as a product. For a foreign application that has only method-of-treatment claims, it is better to decide first, when it enters Korea, whether to change them into claims in the form of a composition.
  • In the specification, we suggest including, at the time of filing, data on the effect that appears at the administration and dosage to be claimed. The Practice Guidelines say that the pharmacological effect that supports the administration and dosage is to be stated at the time of filing. The 2017 decision requires a remarkable effect or an effect of a different kind that could not be predicted.
  • In general, we consider that inventive step is hard to have recognized if the prior art documents contain a close dosage range or half-life data. This is the case where only the dosage and the interval are limited. In this case, the element of the accused invention was held to be easily derived from such material.
  • At the trial stage, administration and dosage are elements for both sides. The legal principle of this decision also applies when determining whether the accused invention is a free-to-work technology.
  • Questions that this decision alone cannot answer need to be reviewed separately. One example is the acts covered by the effect of a patent right limited by administration and dosage.

FAQ

Can a patent be obtained in Korea for a medicine claim limited by administration and dosage?

Yes. The Supreme Court held that administration and dosage can be an element of an invention of a medicine as a product. However, the requirements for patentability, such as novelty and inventive step, must be met. [1]

Can the method of administration be written as a method claim?

An invention of a process that claims the method of treating humans as such is not allowed. The Majority Opinion stated that a medical use invention cannot be allowed as an invention of a process whose subject is the method of treating humans and the like as such. [1]

By what standard is the inventive step of an invention concerning administration and dosage determined?

For inventive step not to be denied, a remarkable effect or an effect of a different kind that a person skilled in the art could not predict must be recognized. This is the standard stated in Supreme Court Decision 2014Hu2702 Decided August 29, 2017. [2]

Was the accused invention in this case held to fall within the scope of the right of the patented invention?

No. The lower court held that the accused invention is a free-to-work technology and so does not fall within the scope of the right. The Supreme Court held that determination to be justified and dismissed the final appeal. [1]

Is this decision still good law?

On 9 October 2026, a search of the case law of the Ministry of Government Legislation did not return an en banc decision that overruled this decision. The definition of a medicine in Art. 96(2) of the Patent Act, which the decision cited, is also unchanged. [6]

How DEFINE IP Law Firm handles this

Before filing in Korea, DEFINE IP Law Firm checks whether the claims contain a limitation of administration or dosage. If they do, we also check whether the specification has statements that support the effect of that limitation. We do not present as the standard of a decision anything that is not in the written judgment. For questions about medical use inventions and administration and dosage claims in Korea, please write to contact@defineip.kr.

Sources

  1. Supreme Court en banc Decision 2014Hu768 Decided May 21, 2015 (대법원 2015. 5. 21. 선고 2014후768 전원합의체 판결). https://www.law.go.kr/판례/(2014후768) (verified 2026-10-09)
  2. Supreme Court Decision 2014Hu2702 Decided August 29, 2017 (대법원 2017. 8. 29. 선고 2014후2702 판결). https://www.law.go.kr/판례/(2014후2702) (verified 2026-10-09)
  3. Supreme Court Decision 90Hu250 Decided March 12, 1991 (대법원 1991. 3. 12. 선고 90후250 판결). https://www.law.go.kr/판례/(90후250) (verified 2026-10-09)
  4. Supreme Court Decision 2006Hu3564 Decided January 30, 2009 (대법원 2009. 1. 30. 선고 2006후3564 판결). https://www.law.go.kr/판례/(2006후3564) (verified 2026-10-09)
  5. Supreme Court Decision 2012Hu3664 Decided May 16, 2014 (대법원 2014. 5. 16. 선고 2012후3664 판결). https://www.law.go.kr/판례/(2012후3664) (verified 2026-10-09)
  6. Patent Act (특허법), Act No. 21134, in force from 2025-11-11. Art. 2, subparagraph 3, Art. 96(2) and Art. 135. The version at the time of the decision (Act No. 13317, in force from 2015-05-18), Art. 2, 96 and 135. The old versions (Act No. 3566 and Act No. 3891), Art. 4, and the Addenda of Act No. 3891. Act No. 14035 (in force from 2017-03-01), Art. 135 and the Addenda. The Addenda of Act No. 16804 and Act No. 20700. The version scheduled to enter into force (Act No. 21955, in force from 2027-03-16), Art. 2, 29, 96 and 135. https://www.law.go.kr/법령/특허법 (verified 2026-10-09)
  7. Ministry of Intellectual Property (지식재산처), Examination Practice Guidelines by Technology Field (기술분야별 심사실무가이드) (March 2026 edition), Chapter V, Examination Practice Guidelines in the Pharmaceutical Field (제5부 의약 분야 심사실무가이드), 1.3, 2.1.1.1, 2.2.1.1, 3.1.1, 3.3.1 and 3.4.1.3. https://www.kipo.go.kr/ko/kpoContentView.do?menuCd=SCD0200147 (verified 2026-10-09)
  8. Ministry of Intellectual Property (지식재산처), Patent Examination Guidelines (특허·실용신안 심사기준), MOIP Established Rule No. 7 (지식재산처예규 제7호), issued 2026-03-12, in force from 2026-03-13. Revision history. https://www.law.go.kr/행정규칙/특허·실용신안심사기준 (verified 2026-10-09)